Today I received a reply from Nick Ede regarding an update on ourHER-Vaxx patients.
To say it is great news is an understatement. It’s actually amazing forIMU and even more so for our patients. The email and response follow ...
_____________
A Quick Question about HER-Vaxx
Good morning,
I am a very long-term holder.
In a release dated 27 June 2022 regarding the HER-Vaxx trial itwas stated ...
The longest HER-Vaxx treated patients remain alive2.5 years (with one patient approaching 3 years) after starting therapy.
I was wondering if these patients were still responding positively(surviving) with the HER-Vaxx treatment?
If so this is an amazing result.
Thank you in anticipation.
(Outlander)
-----------------------------------------
|
Dear XXX, I’m pleased to report the remaining HER-Vaxx patients are still with us, and I agree it’s a very pleasing for the patients and their families. Best regards, Nick Nicholas Ede (PhD)
|
|---|
Well, I can do the Math, as they say.
The remaining patients are now approaching 3.5 years survival (with one approaching 4 years).
Seriously, in the not-too-distant future, IMU may be able to use the ‘C’ word regarding this group of patients.
And that is HER-Vaxx working as a sole-treatment.
Just imagine the reaction if we see positive response with the Keytruda ‘combo’ currently now in play.
Many here will know that @davybabyk, myself, and several others have been big fans of HER-Vaxx for a very long time.
Any deal that comes as a result of these trials will trigger a re-rate of serious propotions. Even before we get the certified
‘data reads’ on the CF33 trials.
As always opinion only. Not financial advice.
(20min delay)